Themis Bioscience

About:

Themis Bioscience is a start-up biotechnology company.

Website: http://www.themisbio.com/

Top Investors: Innovate UK, Merck, Credit Agricole CIB, Wellington Partners, Ventech

Description:

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Total Funding Amount:

$150M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Vienna, Wien, Austria

Founded Date:

2009-09-01

Contact Email:

office(AT)themisbio.com

Founders:

Dr. Erich Tauber

Number of Employees:

11-50

Last Funding Date:

2020-03-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai